未盈利药企迪哲医药完成18亿元定增，生物医药资本市场回暖了吗

Group 1 - The core point of the news is that Dize Pharmaceutical is the first unprofitable company on the Shanghai Stock Exchange to receive registration for refinancing since the release of the "Kebatiaos" policy [1][2] - Dize Pharmaceutical completed a private placement of 1.796 billion yuan, with a share price set at 43.00 yuan per share, involving 24 subscription participants, including public funds and foreign institutional investors [1] - The purpose of the refinancing is to invest in new drug research and development, international standard innovative drug industrialization projects, and to supplement working capital [1] Group 2 - Dize Pharmaceutical has two products, Shuwozhe and Gaoruizhe, that have been launched in China and included in the new national medical insurance catalog, with Shuwozhe's application to the FDA accepted for priority review [1] - The company reported a net loss of 857 million yuan for 2024, which is a reduction of 251 million yuan compared to the previous year [1] - The capital market for biopharmaceuticals is showing signs of recovery, with over half of the 110 stocks in the Sci-Tech Innovation Board's biopharmaceutical sector having positive cumulative returns this year [2]